AstraZeneca PLC

AstraZeneca PLC

175.02
BRL
-1.88
(-1.06%)
6.04EPS
23.04P/E
1.32TMarket Cap
Feb 11Next Earn
AstraZeneca PLC
B3:A1ZN34
(B3)

Recent

price

175.02

P/E

ratio

23.04

div

yld

1.56%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
3.82
4.07
3.66
3.4
3.47
3.22
3
2.93
2.88
3.09
3.35
4.35
4.73
4.88
5.75
6.25
6.64
Revenue per Share
0.92
1.2
0.82
0.34
0.16
0.37
0.46
0.39
0.28
0.17
0.4
0.01
0.35
0.63
0.75
1.09
1.17
Basic EPS, GAAP
0.97
0.79
0.3
0.7
0.56
0.07
0.24
0.26
0.16
0.06
0.28
0.44
0.77
0.7
0.77
0.92
0.65
Free Cash Flow per Basic Share
0.39
0.46
0.48
0.46
0.46
0.45
0.46
0.46
0.45
0.46
0.45
0.45
0.46
0.48
0.49
0.53
0.53
Dividend per Share
2.72
2.97
3.14
3.05
2.56
2.41
1.94
1.95
1.62
1.65
1.96
4.18
3.94
4.16
4.34
5.18
5.5
Book Value per Share
0.14
0.31
-0.35
-0.37
-1.68
-2.08
-3.18
-3
-2.76
-2.44
-2.16
-2.46
-2.35
-2.02
-1.85
-1.11
-0.81
Tangible Book Value per Share
8,718
8,252
7,645
7,591
7,651
7,663
7,670
7,676
7,682
7,888
7,954
8,597
9,385
9,391
9,397
9,397
9,400
Basic Weighted Avg Shares
33,269
33,591
27,973
25,806
26,547
24,708
23,002
22,465
22,090
24,384
26,617
37,417
44,351
45,811
54,073
58,739
62,384
Sales/Revenue/Turnover
34.72
33.58
28.19
14.33
11
12.41
21.02
12.06
2.34
2.12
14.71
-0.37
10.17
19.04
18.96
22.69
23.68
Operating Margin (%)
2,741
2,550
2,518
4,583
3,282
2,852
2,357
3,036
3,753
3,762
2,896
4,102
5,254
5,387
5,065
5,490
6,168
Depreciation Expense
8,053
9,917
6,240
2,556
1,233
2,825
3,499
3,001
2,155
1,335
3,196
112
3,288
5,955
7,035
10,225
11,030
Net Income, GAAP
26.38
18.99
18
21.3
0.88
7.92
4.11
- -
- -
20.74
19.71
- -
- -
13.6
18.99
17.49
17.04
Effective Tax Rate (%)
24.21
29.52
22.31
9.9
4.64
11.43
15.21
13.36
9.76
5.47
12.01
0.3
7.41
13
13.01
17.41
17.68
Profit Margin (%)
8,344
7,754
5,145
4,284
-633
1,138
-1,994
-3,233
-701
-2,554
-763
3,650
-3,700
-5,488
-2,039
-1,894
181
Working Capital
9,097
7,338
9,409
8,588
8,397
14,137
14,501
15,560
17,359
16,217
17,994
28,888
23,690
23,222
27,619
26,136
28,797
LT Debt
23,410
23,466
23,946
23,253
19,646
18,509
16,669
16,642
14,044
14,596
15,638
39,287
37,058
39,166
40,871
48,719
51,814
Total Equity
21.89
27.32
18.21
7.88
6.07
11.11
13.38
- -
- -
6.72
11.51
- -
- -
10.33
11.38
14.9
14.64
Return on Invested Capital (%)
27.21
31.59
19.79
8.63
6.82
11.81
14.63
- -
- -
7.74
12.4
- -
- -
10.95
12.11
15.52
15.2
Return on Capital (%)
36.71
42.7
26.57
10.89
5.75
14.82
20.99
20.13
15.71
10.43
22.23
0.41
8.62
15.63
17.6
22.86
22.6
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
7,959
6,234
5,394
LT Borrowings
24,454
23,683
26,465
LT Finance Leases
1,505
2,322
2,332
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
9,403
9,403
9,403
Market Capitalization
306,820
295,235
254,175

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
29,613
27,965
31,448
Cash, Cash Equivalents & STI
7,675
4,968
8,166
Accounts Receivable, Net
14,106
14,330
14,736
Inventories
6,570
6,932
6,883
Total Current Liabilities
32,570
31,553
31,267
Payables & Accruals
- -
- -
- -
ST Debt
7,959
6,234
5,394
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
16.02%
34.96%
19.2%
Free Cash Flow
66.85%
36.92%
19.18%
Net Income, GAAP
296.66%
576.76%
45.34%
Sales/Revenue/Turnover
9.77%
17.81%
8.63%
Total Cash Common Dividend
3.7%
6.9%
7.39%

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
12,679
12,938
13,565
14,891
54,073
2025
13,588
14,457
15,191
15,503
58,739
2026
15,288
15,384
16,209
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.23
0.21
0.15
0.16
0.75
2025
0.31
0.26
1.63
0.25
1.09
2026
0.33
0.27
0.33
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.32
- -
0.17
- -
0.49
2025
0.36
- -
1.04
- -
0.53
2026
0.35
- -
0.18
- -
- -
Business
AstraZeneca PLC (AZN.L), a British-Swedish multinational biopharmaceutical company headquartered in Cambridge, United Kingdom, and founded in 1999 through the merger of Sweden's Astra AB and the UK's Zeneca Group PLC, discovers, develops, manufactures and commercializes prescription medicines across three core therapy areas: Oncology; BioPharmaceuticals, including Cardiovascular, Renal & Metabolism (CVRM) products such as Farxiga (dapagliflozin) for heart failure, chronic kidney disease and type 2 diabetes, Lokelma (sodium zirconium cyclosilicate) for hyperkalaemia, and Brilinta (ticagrelor) for cardiovascular disease, as well as Respiratory & Immunology offerings including Symbicort (budesonide/formoterol), Breztri (budesonide/glycopyrronium/formoterol), Fasenra (benralizumab) for severe eosinophilic asthma and EGPA, Saphnelo (anifrolumab) for systemic lupus erythematosus, and Pulmicort (budesonide); Rare Disease and BioPharmaceuticals treatments; and Vaccines & Immune Therapies; with key Oncology brands encompassing Tagrisso (osimertinib) for EGFR-mutant non-small cell lung cancer, Imfinzi (durvalumab) for bladder cancer, lung cancer and gastric cancers, Lynparza (olaparib) as a PARP inhibitor across ovarian, breast, prostate and pancreatic cancers, Enhertu (trastuzumab deruxtecan) for HER2-positive breast, gastric and other cancers, and Calquence (acalabrutinib) for haematological malignancies. The company conducts R&D at major sites in Cambridge (UK), Gaithersburg (Maryland, US), Gothenburg (Sweden) and Warsaw (Poland), operates sales in over 130 countries with more than 80,000 employees worldwide, and maintains manufacturing facilities across the US, Europe and other regions. Recent developments include the acquisition of Belgian biotech EsoBiotec for up to $1 billion in March 2025 to advance in vivo cell therapy platform ENaBL for cancer treatments; exercise of an option to acquire obesity-focused startup SixPeaks Bio AG in October 2025; completion of the acquisition of Amolyt Pharma for $1.05 billion to bolster rare endocrine disease pipeline; a licensing deal with Algen Biotechnologies in October 2025 worth up to $555 million for AI-identified gene therapies targeting immune disorders; a collaboration with Alteogen for subcutaneous oncology formulations using Hybrozyme technology; significant US manufacturing expansions such as a $445 million facility upgrade in Coppell, Texas, to double Lokelma production, a new $4.5 billion API plant in Virginia, and a $2 billion investment in Maryland for biologics and clinical production; alongside positive clinical trial readouts for Enhertu in breast cancer, Imfinzi in bladder and gastric cancers, baxdrostat in hypertension, Breztri in asthma, and Fasenra in hypereosinophilic syndrome, with plans for at least 15 new drug launches by 2030.

Company News

  • AstraZeneca Stock Up 12% in a Month: Time to Buy, Sell or Hold?

  • AstraZeneca Secures US, EU Nod for New Myasthenia Gravis Drug Klygefa

  • Summit's FDA Setback Is a Reality Check for Next-Gen Cancer Drugs

  • Breakfast News: Summit’s FDA Setback Isn’t the End

  • Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer

  • AstraZeneca cuts 600 sales jobs in US, Bloomberg News reports

  • EU panel backs AstraZeneca hypertension drug baxdrostat

  • AlphaCore Capital LLC Buys 3,357 Shares of AstraZeneca Plc $AZN

  • AstraZeneca's Oncology Growth Is Outrunning The Farxiga Decline

  • AstraZeneca awards $1.6 million for programs to improve access to healthcare for patients across the US

  • Omniose Announces Its Acquisition by AstraZeneca

  • 7,250 Shares of AstraZeneca Plc $AZN Purchased by CenterBook Partners LP

  • AstraZeneca Plc $AZN Stock: Ethic Inc. Grows Holdings

  • AstraZeneca Plc (NYSE:AZN) Stock Has Average Price Target of $206.67 According to Brokerages

  • AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals

  • 27,056 AstraZeneca Plc $AZN Shares Acquired by International Assets Investment Management LLC

  • 1,929,102 Shares of AstraZeneca Plc $AZN Acquired by Bank Julius Baer & Co. Ltd Zurich

  • AstraZeneca: 3 Key Takeaways for Long-Term Investors

  • AstraZeneca (NYSE:AZN) Share Price Crosses Above 200 Day Moving Average – Time to Sell?

  • AstraZeneca Plc $AZN Shares Acquired by Brian Low Financial Group LLC